Tipranavir demonstrates potent and durable treatment response in HIV-positive women.
D004359:Drug Therapy, Combination; D005260:Female; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006679:HIV Seropositivity / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D008297:Male; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D011753:Pyrones / Q000009:adverse effects / Q000627:therapeutic use*; D019438:Ritonavir / Q000627:therapeutic use; D013449:Sulfonamides; D016896:Treatment Outcome
D017320:HIV Protease Inhibitors; D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; D019438:Ritonavir; C107201:tipranavir